Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile

Autor: Monath, Thomas P., Kortekaas, Jeroen, Watts, Douglas M., Christofferson, Rebecca C., Desiree LaBeaud, Angelle, Gowen, Brian B, Peters, Clarence J., Smith, Darci R., Swanepoel, Robert, Morrill, John C., Ksiazek, Thomas G., Pittman, Phillip R, Nichol, Stuart T., Bird, Brian H., Bettinger, George
Zdroj: In Vaccine: X 7 August 2020 5
Databáze: ScienceDirect